Your session is about to expire
← Back to Search
Physical Therapy Technique
INF + Dietary Education for Diabetic Neuropathy
N/A
Recruiting
Led By Eric G Johnson, DSc, MS-HPEd
Research Sponsored by Loma Linda University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Moderate to severe DPN (diabetic peripheral neuropathy) with symptoms below the knees of numbness, tingling, burning, sharp pain, and/or increased sensitivity
Independent in daily activities
Must not have
End stage congestive heart failure
Lower extremity amputations and open wounds
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change between baseline and 3 months post enrollment.
Awards & highlights
No Placebo-Only Group
Summary
This trial compares INF, a physical therapy, with dietary education to see if it helps adults with DSPN improve circulation.
Who is the study for?
This trial is for adults aged 50-75 with Type II diabetes and moderate to severe diabetic peripheral neuropathy (DPN), specifically the distal symmetric polyneuropathy (DSPN) type. Participants should be able to perform daily activities without walking aids. Excluded are pregnant individuals, those with certain medical conditions or dietary restrictions, metal allergies, or undergoing specific treatments like chemotherapy.
What is being tested?
The study aims to assess if adding gluten-free dietary education enhances the benefits of Intraneural Facilitation™ (INF), a physical therapy technique that may improve circulation in people suffering from DSPN due to diabetes.
What are the potential side effects?
While INF is generally considered safe, potential side effects might include temporary discomfort at the treatment site. Dietary changes can sometimes lead to gastrointestinal adjustments or nutritional imbalances if not properly managed.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I experience numbness, tingling, or pain in my legs due to diabetes.
Select...
I can take care of my daily needs by myself.
Select...
I do not use any devices to help me walk.
Select...
I have a specific type of nerve damage in my hands and feet.
Select...
I have been diagnosed with Type II diabetes.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have advanced heart failure.
Select...
I have had a leg or foot amputation or have open wounds.
Select...
I have a long-term liver condition.
Select...
I am currently undergoing chemotherapy, radiation, or dialysis.
Select...
I am extremely overweight.
Select...
I am currently experiencing inflammation.
Select...
I have advanced COPD.
Select...
My blood pressure is not well-controlled.
Select...
My kidneys are in the final stage of failure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change between baseline and 3 months post enrollment.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between baseline and 3 months post enrollment.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Balance Stability
Neuropathy Severity
Pain Intensity Level
Secondary study objectives
Gluten Consumption Assessment
Pain Quality Assessment
Sleep Quality Assessment
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intraneural Facilitation® Therapy (INF® Therapy) + Dietary EducationExperimental Treatment1 Intervention
The INF® Therapy+ group will receive dietary education with weekly follow-up by a physical therapist either in person, or via email or text message. The INF® Therapy+ group will additionally receive meal preparation ideas and sample menus promoting a gluten-free diet.
Group II: Intraneural Facilitation® Therapy (INF® Therapy)Active Control1 Intervention
INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to "pressurize the entire system" The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside "holding" chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or "holds" are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.
Find a Location
Who is running the clinical trial?
Loma Linda UniversityLead Sponsor
315 Previous Clinical Trials
266,520 Total Patients Enrolled
Eric G Johnson, DSc, MS-HPEdPrincipal InvestigatorDepartment of Physical Therapy School of Allied Health Professions, Loma Linda University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am committed to working on improving my nerve pain symptoms.I am between 50 and 75 years old.I am currently experiencing inflammation.I am currently undergoing chemotherapy, radiation, or dialysis.I am extremely overweight.I am receiving treatment for a long-term health condition.I do not use any devices to help me walk.My blood pressure is not well-controlled.I have advanced COPD.I can take care of my daily needs by myself.I have advanced heart failure.I experience numbness, tingling, or pain in my legs due to diabetes.I have had a leg or foot amputation or have open wounds.I have a neuropathy not caused by diabetes or B12 deficiency.I have a long-term liver condition.I have a specific type of nerve damage in my hands and feet.My kidneys are in the final stage of failure.You have a known problem with using drugs or alcohol.You are pregnant and have reported it yourself.You are allergic to chrome, nickel, or cobalt.You are currently following a mostly plant-based or gluten-free diet.I have been diagnosed with Type II diabetes.
Research Study Groups:
This trial has the following groups:- Group 1: Intraneural Facilitation® Therapy (INF® Therapy)
- Group 2: Intraneural Facilitation® Therapy (INF® Therapy) + Dietary Education
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger